Precision Medicine (PRIVATE.PRECISION)

Overall impact
A (81)

Commentary

Precision Medicine is a leader for overall positive impact. With an 'A' rating of 80.7 for overall impact (95th percentile compared to all companies), Precision Medicine ranks 6th out of 76 industry peers, behind Planet Innovation, Parexel International, Icon and 2 others, and ahead of IMAC, Enzo Biochem, Invitae and 67 others. On top material causes for Precision Medicine's industry (Healthcare Software & Services), Precision Medicine performs well in Accountable Institutions (85.6 score), Child and Maternal Health (95.9), Disease Eradication (96.3) and 7 other causes where it received an 'A' score. Precision Medicine did not receive a 'D' or 'F' rating on any cause.
Impact
Cause PRIVATE.PRECISION
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2,500
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Maryland, United States
Share classes
PRIVATE.PRECISION
Description
Operator of a clinical research organization with specialization in the field of precision medicine. The company offers integrated infrastructure, laboratory expertise, clinical trial and advanced data science services that deliver critical insights into patient biology from early development through approval. Thus, it supports pharmaceutical and life sciences companies in developing new products.
Material causes
Ethos considers the following causes material for Precision Medicine, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.